Unfortunately, we don't support Internet Explorer anymore as it has been replaced by Microsoft Edge. Please try using Edge or an alternative modern browser for the best experience.
Dr. Martin Mackay is the Co-Founder and CEO of Rallybio, a biotech start-up dedicated to developing transformative treatments for patients with rare and ultra-rare diseases.
Prior to this, he was Executive Vice President, Global Head of Research and Development at Alexion Pharmaceuticals. In his role, Dr. Mackay focused on building and improving Alexion’s global research and development organization, with a goal of accelerating the simultaneous development of multiple drug candidates in debilitating and life-threatening ultra-rare disorders across a range of therapeutic areas.
Dr. Mackay has more than 30 years of experience in drug discovery and development on a global scale. Prior to joining Alexion in 2013, Dr. Mackay served as President, Research and Development at AstraZeneca, where he led all R&D functions worldwide, including discovery research, clinical development, regulatory affairs and key related R&D functions. Before joining AstraZeneca, Dr. Mackay held positions of increasing responsibility at Pfizer, rising to the position of President, Head of Pfizer Pharmatherapeutics, R&D, where he oversaw all aspects of discovery and development across nine therapeutic areas. Earlier in his career, Dr. Mackay worked in the CIBA organization (now Novartis) and held positions within academia.
Dr. Mackay conducted his post-doctoral research fellowship in malaria vaccines. He earned a Microbiology First Class Honors Degree from Heriot-Watt University, Scotland, and a Ph.D. in Molecular Genetics from the University of Edinburgh, Scotland.
Dr. Mackay co-chairs the US-India BioPharma & Healthcare Summit Advisory Board and is on the Boards of Charles River Laboratories and Novo Nordisk.
